Abstract 2471: Comparison of the Angiographic and Clinical Benefit of Different Types of Drug-Eluting Stents when Used Instead of Bare-Metal Stents
There are different types of drug-eluting stents (DES) commercially available in Europe. The aim was to compare the angiographic and clinical benefit of these different types of DES when used instead of bare-metal stents (BMS). We identified 21 randomized trials comparing commercially available DES in Europe against BMS: 10 with Cypher (n=3,362 patients), 6 with Taxus (n=3,529 patients), 3 with everolimus-DES (n=153 patients), 1 with Endeavor (n=1,197 patients), and 1 with Janus (n=332 patients). In each of the trials, the clinical benefit (NNT [number of patients needed to be treated to prevent an event] for new revascularization procedures) and angiographic benefit (NNT for binary angiographic restenosis, and reduction in in-stent late loss in comparison with each allocated group to BMS [Δ-ISLL]). The results were weighted for the number of patients included in each trial, calculating the mean value for each type of DES.
Results: The highest angiographic and clinical benefit of using DES instead of BMS was observed with the Cypher stent (highest value of Δ-ISLL and lowest NNT for binary angiographic restenosis and for TLR), and the lowest angiographic benefit occurred with the Janus stent (lowest value of Δ-ISLL, and highest NNT for binary angiographic restenosis and for TLR) (see figure⇓).
Conclusion: the angiographic and clinical benefit of using DES instead of BMS significantly differ among different available types of DES.